Tagged with trials

China Amidst the sea of Big Pharma executives jumping ship to start highly regarded and attention-grabbing biotech companies, bolstered by the huge influx of capital, the opening of stock exchanges in first Hong Kong and subsequently Shanghai to pre-profit biotech companies that meet certain criteria, as well as the reformation and…

USA Paul Bleicher, CEO at OptumLabs, and one of the speakers at the FT US Pharma & Biotech Summit on May 14, shares insights on the benefits we will see AI bring to pharma companies and patients in the short and long term, as well as use cases for the technology.…

Egypt Basyouni Abuseif, country president and CPO Head at Novartis Egypt, explains how the Swiss company has taken over the leadership position in the Egyptian pharmaceutical market despite economic and political challenges. He also highlights recent achievements of the government in fighting Hepatitis C, while emphasizing the need for more attention…

France Bertrand Sohier, VP and general manager business and administration of Parexel France discusses the latest trends impacting the clinical research environment of the country, gives insight on the strategies the company utilizes to differentiate itself from competitors, and shares the importance of keeping a patient-focused mentality at the core of…

Spain Aurora Berra, general manager of Sobi Spain and Portugal, highlights her key priorities and the opportunities and challenges inherent in the fragmented Spanish healthcare system. Berra gives insight into the need for a bespoke rare disease focus and delivers advice to young women starting their journey in the healthcare industry.…

Egypt Mohamed Swilam, country manager of Roche Egypt, explains how ensuring access to medicine in Egypt is not only related to pricing challenges, but also to support healthcare systems, improve diagnosis, educate and build local skills. He also gives insights into the company’s plans on how to partner with stakeholders across…

Korea Dr Jin Hyoung Kang, president of the Cancer Study Group comments on the scope for oncology drug development in Korea, and the issues resulting from the structure of Korea’s healthcare system. Dr Kang also offers his foresight in relation to the greater role AI and big data will play within…

Opinion Drug development in rare diseases is currently in a very exciting time. While much of the focus is on the scientific advances,  access to rare disease patients and well-designed clinical trials are also essential to evaluating new therapeutics. In this article, PJ Brooks, Program Director at the Office of Rare…

Spain Silvia Casellas, CEO of Anagram, a Spanish CRO, discusses the challenges of the consolidation process the company has gone in recent years, the reasons for the boom in Spain’s clinical trials ecosystem, and the importance of a close-knit client-to-service-provider relationship for CROs today.   We are the first Spanish company…

China Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to leave Pfizer to establish dMed; the mission of dMed as ‘more than a CRO’ to support the growth of the Chinese biotech industry; their…

Spain Alfonso García Cañamaque, CEO of León Research, gives an overview of the Spanish clinical research ecosystem and the challenges facing CROs. Also, he explains the differentiating factor of the company and internationalization strategy moving forward as they position themselves as the partner of choice.   One of our challenges is…

Spain Having largely recovered from the impact of the global financial crisis and with several impressive fundamentals in place, Spain once again stands as one of Europe’s premier healthcare and life science investment destinations.   These fundamentals include a revamped market access process that puts the Iberian nation on a par…